Aequus Pharmaceuticals Total Debt vs. Retained Earnings
| AQSZF Stock | USD 0.01 0.0005 7.04% |
For Aequus Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Aequus Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Aequus Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Aequus Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Aequus Pharmaceuticals over time as well as its relative position and ranking within its peers.
Aequus |
Aequus Pharmaceuticals Retained Earnings vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Aequus Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Aequus Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Aequus Pharmaceuticals is rated below average in total debt category among its peers. It is number one stock in retained earnings category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aequus Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Aequus Total Debt vs. Competition
Aequus Pharmaceuticals is rated below average in total debt category among its peers. Total debt of Health Care industry is presently estimated at about 41.25 Million. Aequus Pharmaceuticals adds roughly 26,087 in total debt claiming only tiny portion of equities under Health Care industry.
Aequus Retained Earnings vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Aequus Pharmaceuticals |
| = | 26.09 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Aequus Pharmaceuticals |
| = | (5.72 M) |
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
Aequus Retained Earnings Comparison
Aequus Pharmaceuticals is currently under evaluation in retained earnings category among its peers.
Aequus Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Aequus Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Aequus Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Aequus Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Aequus Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada. Aequus Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 14 people.
Aequus Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Aequus Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Aequus Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Aequus Pharmaceuticals' important profitability drivers and their relationship over time.
Use Aequus Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aequus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aequus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Aequus Pharmaceuticals Pair Trading
Aequus Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Aequus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aequus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aequus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aequus Pharmaceuticals to buy it.
The correlation of Aequus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aequus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aequus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aequus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Aequus Pharmaceuticals position
In addition to having Aequus Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Military Industrial Thematic Idea Now
Military Industrial
A collection of large United States defense contractors including companies involved in production or distribution of aircraft, ships, vehicles, weaponry, and electronic systems in cooperation with the government. The Military Industrial theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Military Industrial Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Aequus OTC Stock
To fully project Aequus Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Aequus Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Aequus Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.